Migraine is a common neurological disorder involving repeated headaches and associated phenomena. It is a leading cause of disability throughout the world. It has a multifactorial background (genetic, environmental, metabolic, hormonal, pharmacological) and triggers that vary between patients. However, it presents a common pattern of occurrence, with peak incidence in adolescence and peak prevalence in middle age. Recent research advances have helped to better determine the brain structures involved in migraine and observe physiological changes in patients with the disorder. These advances are the basis for studies of novel therapeutics and prophylactic approaches.

This report provides the current 1-year prevalent population for migraine across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, India, Brazil) split by gender and 5-year age cohort. In addition to the current 1-year prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of migraine patients, as well as the main symptoms of the disease have been quantified and presented alongside the overall 1-year prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main co-morbidities of migraine include:

  • Hypertension (depending on the study)
  • Mood disorders (anxiety, depression)
  • Obesity
  • Abdominal pain
  • Emesis
  • Cyclic vomiting syndrome (in children)
  • Multiple sclerosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global migraine market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the 1-year prevalence of the subdivided types of migraine and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific symptoms on the 1-year prevalent population of migraine patients.
  • Identification of migraine patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of migraine patients.